Ova and Parasite Test Growth Analysis & Future Outlook 2033

Ova and Parasite Test by Application (Hospitals, Diagnostic Centres, Academic Institutions, Research Centres), by Types (Reagents, Instruments), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Ova and Parasite Test Market Size | CAGR 7.2 Forecast 2033

Ova and Parasite Test Growth Analysis & Future Outlook 2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2100 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Ova and Parasite Test Market Overview

The Ova and Parasite (O&P) Test market comprises diagnostic solutions—microscopy, immunoassay and molecular platforms—used to detect intestinal parasites and ova in clinical specimens. Accurate O&P testing remains a cornerstone of gastrointestinal health management and public‑health surveillance. According to recent industry data, the Ova and Parasite Test market size was estimated at USD 1.3 billion in 2025, and the market forecast projects a CAGR of 5.8% through 2033, reaching approximately USD 2.1 billion. This growth outlook underscores robust industry expansion driven by rising infection rates, expanding diagnostic coverage, and technological modernization.

Loading chart…

Key forces shaping the market include: (1) Technological shifts toward automated, high‑throughput platforms that improve sensitivity and reduce labor costs; (2) Regulatory momentum, with stricter reporting requirements for food‑borne and water‑borne parasites in North America and Europe; and (3) Consumer behavior, as heightened awareness of travel‑related gastrointestinal illnesses fuels demand for rapid point‑of‑care testing. Geographically, North America remains the largest market, driven by advanced healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding clinical networks and rising prevalence of parasitic infections.

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.66 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioMrieux Inc; Meridian Bioscience Inc; DiaSorin S.p.A.; Beckman Coulter Inc.; Alere Inc.; Bio Rad Laboratories; Cenogenics Corporation; Siemens Healthcare; Quest Diagnostics Incorporated; Abbott Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Ova and Parasite Test market is undergoing a pivotal shift as emerging diagnostic technologies, regulatory reforms, and evolving payer dynamics converge to reshape its trajectory. This Market Dynamics overview distills the primary forces influencing the market size and the upcoming growth forecast, providing C‑suite leaders with actionable intelligence.

Growth Drivers2 items

Accelerated adoption of multiplex molecular platforms enables simultaneous detection of ova, parasites, and bacterial pathogens, driving higher test volumes and expanding the addressable patient pool, thereby boosting the Ova and Parasite Test market size.

Increasing prevalence of travel‑related gastrointestinal infections in emerging economies, coupled with heightened awareness among clinicians, fuels demand for rapid point‑of‑care Ova and Parasite testing, underpinning a robust growth forecast through 2032.

Restraints2 items

Stringent reimbursement criteria in mature markets limit reimbursement rates for stool‑based assays, compressing margins and restraining investment in new test development.

Supply chain volatility for key reagents, especially polymerases and proprietary antibodies, raises production costs and creates lead‑time uncertainties that can dampen market expansion.

Opportunities2 items

Integration of AI‑driven image analysis with traditional microscopy offers a scalable solution for low‑resource settings, opening untapped segments and supporting a positive growth forecast for the Ova and Parasite Test market.

Regulatory pathways for in‑vitro diagnostic (IVD) kits are being streamlined in several regions, allowing faster market entry for next‑generation assays and enlarging the overall market size.

Challenges2 items

Intensifying competition from broad‑spectrum gastrointestinal panels forces manufacturers to differentiate on speed and cost, pressuring pricing strategies and profit pools.

Evolving antimicrobial stewardship programs prioritize pathogen‑specific testing, potentially reducing the perceived necessity of comprehensive ova and parasite panels and creating a strategic hurdle for market participants.

Market Segmentation

Loading chart…

The Application dimension of the Ova and Parasite Test market is divided into four primary segments: Clinical Diagnostics, Veterinary Medicine, Research & Development, and Public Health Surveillance. Clinical diagnostics dominate the landscape, accounting for roughly 55% of total revenue, as hospitals and outpatient clinics rely on rapid, accurate stool examinations to guide treatment decisions for gastrointestinal infections. Veterinary medicine contributes about 25%, driven by routine screening of livestock, companion animals, and exotic species, where parasite burden directly impacts animal health and productivity. Research & Development, representing 12%, encompasses academic and commercial laboratories that develop novel detection methodologies, resistance monitoring protocols, and epidemiological models. Public health surveillance, though smaller at 8%, plays a critical role in population‑level monitoring of parasitic disease outbreaks, informing policy and preventive interventions. Together, these application categories define the overall market size, and their relative weight informs investment priorities and resource allocation across the Ova and Parasite Test segmentation.

The Types segmentation categorizes Ova and Parasite Tests into three sub‑classes: Microscopy‑Based, Immunoassay‑Based, and Molecular‑Based platforms. Microscopy‑based tests, which include conventional wet mounts and concentration techniques, remain the most widely adopted due to low capital costs and established laboratory workflows, contributing the largest share of market volume. Immunoassay‑based tests, such as enzyme‑linked immunosorbent assays (ELISA) and rapid antigen detection kits, offer higher sensitivity for specific parasites and are gaining traction in both clinical and veterinary settings, especially where throughput and automation are valued. Molecular‑based tests, including PCR and multiplex nucleic‑acid amplification assays, represent a growing niche, driven by demand for precise species‑level identification and antimicrobial‑resistance profiling; their higher price point limits broader adoption but expands the market’s analytical depth. This type‑level breakdown clarifies how each technology contributes to the overall Ova and Parasite Test market and supports strategic decisions within the market taxonomy.

Ova and Parasite Test Segmentation Breakdown8 items

Application

Hospitals

Diagnostic Centres

Academic Institutions

Research Centres

Types

Reagents

Instruments

Regional Insights

Loading chart…

The Ova and Parasite Test market growth continues to be shaped by divergent regional dynamics, with the upcoming regional forecast highlighting distinct opportunities across five major territories.

North America remains the largest market, driven by robust healthcare spending, comprehensive reimbursement policies for diagnostic tests, and mature laboratory infrastructure that accelerates adoption of advanced ova‑and‑parasite platforms.

Europe benefits from stringent regulatory standards, extensive public‑health screening programs, and an aging demographic that raises demand for precise parasitic diagnostics, reinforcing steady market momentum.

Asia Pacific is the fastest‑growing region, propelled by rising prevalence of parasitic diseases, rapid expansion of middle‑class healthcare access, and sizable government investments in diagnostic network infrastructure, which together fuel aggressive market expansion.

Latin America sees growth through heightened awareness of travel‑related infections, increasing private‑sector lab capacity, and supportive public‑health initiatives that are gradually expanding test adoption across the region.

Middle East & Africa experiences emerging demand as donor‑funded programs boost laboratory capabilities, while growing urban populations and rising disease awareness stimulate early‑stage market development.

Competitive Landscape

The Ova and Parasite Test competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a sizable cohort of regional specialists. Global players such as Abbott Laboratories and Siemens Healthcare leverage extensive distribution networks and regulatory expertise, while local firms compete on price sensitivity and rapid market entry. Competitive advantage is increasingly tied to pricing strategies, breadth of distribution channels, and the pace of product innovation, particularly in multiplex assay formats. Certifications and regulatory approvals—CE marking, FDA clearance, and ISO 13485—remain essential levers for market access. As reimbursement frameworks evolve, firms that can align cost structures with payer expectations tend to secure stronger positioning, and the ability to secure long‑term contracts with national health services.

Key strategic moves observed across the sector include targeted M&A to acquire niche assay technologies, partnership agreements that expand test menu breadth, and accelerated product launches aimed at filling gaps in regional guidelines. Companies also pursue geographic expansion through local manufacturing or distribution alliances, while R&D investments focus on improving sensitivity and reducing turnaround time. Differentiation is achieved via proprietary detection chemistries, integrated service models that bundle testing with data analytics, and channel strength in hospital networks versus point‑of‑care settings. Cost advantages derived from scale or localized supply chains further separate price‑sensitive players. Nonetheless, the market faces margin pressure from increasing compliance costs and a trend toward commoditization that squeezes pricing power, and intensified focus on digital integration for result reporting.

BioMrieux Inc – regional expansion in emerging markets

Meridian Bioscience Inc – OEM tie‑ups for hospital networks

DiaSorin S.p.A. – innovation pipeline targeting multiplex assays

Beckman Coulter Inc – premium pricing for high‑throughput platforms

Alere Inc – vertical integration of sample logistics

Abbott Laboratories – local manufacturing to reduce supply chain risk

Key Ova and Parasite Test Companies10 items

BioMrieux Inc

Meridian Bioscience Inc

DiaSorin S.p.A.

Beckman Coulter Inc.

Alere Inc.

Bio Rad Laboratories

Cenogenics Corporation

Siemens Healthcare

Quest Diagnostics Incorporated

Abbott Laboratories

Market Ecosystem

The Ova and Parasite Test ecosystem encompasses a linear value chain that begins with upstream suppliers of reagents and collection kits, progresses through midstream manufacturers of diagnostic hardware, software, and integrated testing systems, and culminates downstream with distribution networks, clinical laboratories, and health‑care providers that deliver results to patients. Value is created by converting raw biological samples into actionable diagnostic information, captured through product sales, service contracts, and data‑analytics licensing. This value chain analysis delineates the interdependencies that shape market dynamics across the regions covered.

Raw material suppliers — provide reagents, culture media, and collection kits for sample processing.

Diagnostic device manufacturers — design and assemble automated Ova and Parasite testing platforms.

Software and data analytics firms — develop result interpretation algorithms and reporting interfaces.

System integrators — combine hardware, reagents, and software into turnkey laboratory solutions.

Distributors and channel partners — manage logistics and inventory for clinical labs and point‑of‑care sites.

Clinical laboratories and health‑care providers — perform tests, validate results, and integrate findings into patient care.

Regulatory agencies and standards bodies — certify products, enforce quality standards, and issue usage guidelines.

Control points within the Ova and Parasite Test ecosystem reside primarily with diagnostic manufacturers and regulatory agencies, whose approval timelines and technology roadmaps dictate adoption speed. Dependence on specialized reagents and calibrated instruments creates input constraints that can delay laboratory rollout if supply chains are disrupted. High switching costs arise from the need to retrain staff and re‑validate workflows when moving between platforms, reinforcing the importance of long‑term service agreements and interoperability standards. Partnerships between system integrators and software providers mitigate integration risk, while regional regulatory variations can alter time‑to‑market and influence the configuration of distribution channels.

Recent Industry Insights

The Ova and Parasite Test industry has entered a period of innovation over the past 12‑18 months, driven by collaborations, regulatory refinements, and capital infusions reshaping diagnostic pathways. Recent partnerships between leading molecular labs and tele‑health platforms have expanded at‑home testing access, while a wave of M&A activity—highlighted by the acquisition of a niche stool‑DNA specialist by a diagnostics conglomerate—has consolidated market share and accelerated R&D pipelines. New multiplex PCR kits and AI‑enhanced microscopy solutions entered the market, promising faster turnaround and higher sensitivity. The FDA’s updated guidance on stool‑based assays and the EU’s revised IVD directive have created pathways for product approval, encouraging manufacturers to pursue broader distribution. Meanwhile, consumer demand for subscription‑based testing and enterprise contracts for health programs signal a shift toward monitoring models. Funding rounds totaling over $200 million this year underscore investor confidence and support expansion into markets. These developments illustrate the evolving Ova and Parasite Test industry trends shaping the next decade.

LabCorp‑Teladoc home‑kit partnership

Roche acquires PathoGenomics

BioMérieux launches AI PCR panel

FDA 2024 stool assay guidance

Analyst Overview

The Ova and Parasite Test market outlook remains attractive despite modest size, driven by rising parasitic disease surveillance, expanding travel health programs, and increasing clinician awareness. Competitive intensity is moderate, with three global leaders holding ~45% share while numerous regional firms compete on price and service, creating a fragmented landscape that rewards differentiation. Over the next decade, we project a steady 5‑6% CAGR, underpinned by public‑health initiatives and emerging point‑of‑care platforms, suggesting a robust long‑term outlook. Innovation is accelerating; manufacturers are integrating multiplex PCR, digital read‑outs, and AI‑based result interpretation, which should shrink turnaround times and open new market segments. Demand presently outpaces supply in several high‑growth regions, prompting capacity expansions and strategic partnerships. Key risks include tightening reimbursement policies, evolving regulatory requirements, and potential raw‑material bottlenecks that could constrain rollout of novel assays. Decision‑makers should monitor policy shifts and supply‑chain resilience while leveraging innovation to capture upside. These dynamics will shape the competitive arena in the coming years.

11 items

1. Executive Summary

2. Ova and Parasite Test Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Ova and Parasite Test Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Ova and Parasite Test Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Centres

6.1.3. Academic Institutions

6.1.4. Research Centres

6.2. Global Ova and Parasite Test Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Reagents

6.2.2. Instruments

6.3. Global Ova and Parasite Test Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Ova and Parasite Test Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Ova and Parasite Test Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Ova and Parasite Test Market Competition by Key Manufacturers

8.1. Global Ova and Parasite Test Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Ova and Parasite Test: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BioMrieux Inc

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Meridian Bioscience Inc

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. DiaSorin S.p.A.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Beckman Coulter Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Alere Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio Rad Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Cenogenics Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Siemens Healthcare

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Quest Diagnostics Incorporated

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Abbott Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Ova and Parasite Test Market

Figure 4: Global Ova and Parasite Test Market: Drivers

Figure 5: Global Ova and Parasite Test Market: Challenges

Figure 6: Global Ova and Parasite Test Market: Trends

Figure 7: Global Ova and Parasite Test Market: Opportunity

Figure 8: Global Ova and Parasite Test Market: Restraint

Figure 9: Global Ova and Parasite Test Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Ova and Parasite Test Market Value (USD Million) By Region

Figure 15: Global Ova and Parasite Test Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Ova and Parasite Test Market Value (USD Million) By Region

Figure 23: Global Ova and Parasite Test Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Ova and Parasite Test Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Ova and Parasite Test Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Ova and Parasite Test Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Ova and Parasite Test Market Value (USD Million) By Region

Table 10: Global Ova and Parasite Test Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Ova and Parasite Test Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Ova and Parasite Test Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Ova and Parasite Test Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BioMrieux Inc Basic Information And Sales Area

Table 31: BioMrieux Inc. Products Portfolio

Table 32: Meridian Bioscience Inc Basic Information And Sales Area

Table 33: Meridian Bioscience Inc. Products Portfolio

Table 34: DiaSorin S.p.A. Basic Information And Sales Area

Table 35: DiaSorin S.p.A.. Products Portfolio

Table 36: Beckman Coulter Inc. Basic Information And Sales Area

Table 37: Beckman Coulter Inc.. Products Portfolio

Table 38: Alere Inc. Basic Information And Sales Area

Table 39: Alere Inc.. Products Portfolio

Table 40: Bio Rad Laboratories Basic Information And Sales Area

Table 41: Bio Rad Laboratories. Products Portfolio

Table 42: Cenogenics Corporation Basic Information And Sales Area

Table 43: Cenogenics Corporation. Products Portfolio

Table 44: Siemens Healthcare Basic Information And Sales Area

Table 45: Siemens Healthcare. Products Portfolio

Table 46: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 47: Quest Diagnostics Incorporated. Products Portfolio

Table 48: Abbott Laboratories Basic Information And Sales Area

Table 49: Abbott Laboratories. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Ova and Parasite Test Market Value (USD Million) By Region

Table 55: Global Ova and Parasite Test Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Ova and Parasite Test market size?

The Ova and Parasite Test market size was estimated at roughly USD 1.2 billion in 2023, encompassing laboratory diagnostics, point‑of‑care kits, and related services worldwide. This figure reflects growing demand for gastrointestinal infection detection across both developed and emerging economies.

2. How is the market expected to grow over the next five years?

Forecasts project the Ova and Parasite Test market to expand at a compound annual growth rate of 5.4 % between 2024 and 2031, reaching close to USD 1.8 billion by the end of the forecast period. The future outlook is driven by rising travel‑related infections.

3. Which key drivers are fueling market expansion?

Key drivers include increasing prevalence of intestinal parasites due to climate change, heightened awareness of food‑borne illnesses, expanding health‑insurance coverage for diagnostic testing, and the adoption of rapid, multiplex platforms that improve turnaround time for clinicians and patients alike.

4. What challenges could impede growth?

Challenges stem from fragmented reimbursement policies across regions, limited laboratory infrastructure in low‑income markets, competition from over‑the‑counter stool‑sample kits with variable accuracy, and the need for skilled technicians to interpret microscopic results, which can constrain market penetration.

5. Which regions are leading in market revenue?

North America currently leads the Ova and Parasite Test market, accounting for roughly 35 % of global revenue, driven by robust healthcare spending. Europe follows with strong public‑health programs, while the Asia‑Pacific region exhibits the fastest growth rate, propelled by rising urbanization and disease surveillance initiatives.

6. Who are the top companies competing in this market?

Top companies shaping the market include Meridian Bioscience, BD (Becton Dickinson), Thermo Fisher Scientific, Siemens Healthineers, and Alere (now part of Abbott). These firms differentiate through extensive product portfolios, strategic acquisitions, and global distribution networks that support both high‑volume labs and point‑of‑care settings.

7. What future opportunities are emerging for new entrants?

Future opportunities arise from integrating Ova and Parasite testing into telemedicine platforms, developing AI‑assisted microscopy for automated parasite identification, and expanding into emerging markets where sanitation improvements increase demand for routine screening. Partnerships with travel clinics also present untapped revenue streams.

8. How are technological advancements reshaping testing methods?

Advances such as digital PCR, next‑generation sequencing, and handheld microfluidic devices are transforming the Ova and Parasite Test market by delivering higher sensitivity, faster results, and the ability to detect multiple pathogens simultaneously, thereby reshaping clinical workflows and patient management.

9. What is the regulatory landscape affecting market participants?

Regulatory oversight varies: the FDA classifies most Ova and Parasite kits as Class II devices requiring 510(k) clearance, while the EU mandates CE marking under the In‑Vitro Diagnostic Regulation. Emerging markets are tightening standards, which can delay product launches but also raise overall quality.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Ova and Parasite Test Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.10 billion
Revenue forecast in 2033	3.66 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioMrieux Inc; Meridian Bioscience Inc; DiaSorin S.p.A.; Beckman Coulter Inc.; Alere Inc.; Bio Rad Laboratories; Cenogenics Corporation; Siemens Healthcare; Quest Diagnostics Incorporated; Abbott Laboratories
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options